newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

-First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -$316.9 million in cash